Sinomenine

• UNSPSC Description:

  Sinomenine, an alkaloid extracted from?Sinomenium acutum, is a blocker of the NF-κB activation[1]. Sinomenine also is an activator of μ-opioid receptor[2].

• Target Antigen:

  Apoptosis; Autophagy; NF-κB; Opioid Receptor

• Type:

  Natural Products

• Related Pathways:

  Apoptosis;Autophagy;GPCR/G Protein;Neuronal Signaling;NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/sinomenine.html

• Solubility:

  1M HCl : 25 mg/mL (ultrasonic;adjust pH to 1 with HCl)|DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC(C1=C2C[C@@]3([H])[C@](C=C4OC)([H])[C@@]1(CCN3C)CC4=O)=C(C=C2)OC

• Molecular Weight:

  329.39

• References & Citations:

  [1]Song L, et al. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10.|[2]Gao T, et al. Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol. 2013 Dec 5;721(1-3):5-11.|[3]Zhu Q, et al. Antinociceptive effects of sinomenine in a rat model of neuropathic pain. Sci Rep. 2014 Dec 1;4:7270.|[4]Wang MH, et al. Activation of opioid mu-receptor by sinomenine in cell and mice.Neurosci Lett. 2008 Oct 10;443(3):209-12.Acta Pharm Sin B. 2021 Nov;11(11):3465-3480.|Chem Biol Drug Des. 2022 Oct 27.|Drug Des Devel Ther. 2024 Aug 6:18:3523-3545.|Exp Ther Med. 2021 Apr 18.|Heliyon. 2024 June 23.|J Inflamm Res. 2023 Oct 20:16:4777-4791.|Phytother Res. 2023 Apr 10.|PLoS Biol. 2024 June 27.|World J Stem Cells. 2024 May 26.|bioRxiv. 2023 Jun 3.|Free Radic Biol Med. 2018 Jun 2;124:205-213.|Immun Inflamm Dis. 2024 Jun;12(6):e1271.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  115-53-7